| ER、PR和EphA2在乳腺癌中的表达及临床意义 |
| |
| 引用本文： | 赵玉斌,张少华,张积仁,王政江.ER、PR和EphA2在乳腺癌中的表达及临床意义[J].实用肿瘤杂志,2010,25(1):41-44. |
| |
| 作者姓名： | 赵玉斌 张少华 张积仁 王政江 |
| |
| 作者单位： | 1. 南方医科大学珠江医院肿瘤中心,广东,广州,510282
2. 诸城市人民医院心内科,山东,诸城,262200 |
| |
| 摘 要： | 目的探讨乳腺癌组织中雌激素受体（ER）、孕激素受体（PR）和EphA2基因的表达及其与淋巴结转移、临床分期的关系及联合检测对乳腺癌术后治疗方案的制定和在预后中的意义。方法采用S-P免疫组化方法检测130例乳腺癌患者ER、PR和EphA2的表达,并结合临床病理因素进行分析。结果（1）乳腺癌组织中ER、PR和EphA2的阳性表达率分别为63.1%、58.4%和72.3%。（2）ER、PR的阳性表达与乳腺癌患者的年龄、病理组织学类型、肿瘤大小、腋窝淋巴结转移和临床分期无显著相关（P〉0.05）;（3）EphA2阳性表达与乳腺癌患者的年龄、肿瘤大小、病理组织学类型无显著相关（P〉0.05）;而与腋窝淋巴结转移、临床分期显著相关（P〈0.05）。（4）EphA2的阳性表达率在乳腺癌ER／PR阴性组明显高于乳腺癌ER／PR阳性组（P〈0.05）。结论ER、PR和EphA2与乳腺癌的发生、发展有关,联合检测ER、PR和EphA2有助于客观评估乳腺癌的生物学行为,有助于指导临床用药和预测预后。
|
| 关 键 词： | 乳腺肿瘤 受体 雌激素 受体 孕酮 基因 EphA2 淋巴转移 免疫组织化学 |
Expressions of ER,PR and EphA2 in breast cancers and their clinical sigificance |
| |
| ZHAO Yu-bin,ZHANG Shao-hua,ZHANG Ji-ren,et al.Expressions of ER,PR and EphA2 in breast cancers and their clinical sigificance[J].Journal of Practical Oncology,2010,25(1):41-44. |
| |
| Authors: | ZHAO Yu-bin ZHANG Shao-hua ZHANG Ji-ren |
| |
| Institution: | ZHAO Yu-bin1,ZHANG Shao-hua2,ZHANG Ji-ren1,et al (1.Oncology Department of Zhujiang Hospital,Southern Medical University,Guangzhou,510282,China,2.Oncology Department of People\'s Hospital of Zhucheng,Zhucheng,262200,China) |
| |
| Abstract: | Objective To investigate the expressions of ER,PR and EphA2 in breast cancers and their clinical significance.Methods The expressions of ER,PR and EphA2 were detected in 130 cases of breast carcer by immunohistochemistry S-P method.Results(1)The positive rates of expressions of ER,PR and EphA2 were 63.1%,58.4% and 72.3%,respectively.(2)No significant association of expression of ER and PR was noted with age,histological types,tumor size,lymphatic metatasis and clinical stages.(3)The expression of EphA2 was ... |
| |
| Keywords: | breast neoplasms receptors estrogen receptors progesterone genes EphA2 lymphatic metastasis immunohistochemistry |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
